M&A / Deals Biogen to acquire RayThera for up to $1bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones.NeuroscienceRead full story pharminent June 19, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA experts endorse Moderna’s mRNA seasonal flu shotNext: US launches probe of German ‘underpayment’ for medicines Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
